Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind randomized study of bevacizumab in glioblastoma (MO28347 continuation)
2012-003138-17Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by Roche. Started Apr 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2012-003138-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003138-17.